+

PE20181072A1 - Composicion farmaceutica que contiene 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}-n-(metilsulfonil)acetamida - Google Patents

Composicion farmaceutica que contiene 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}-n-(metilsulfonil)acetamida

Info

Publication number
PE20181072A1
PE20181072A1 PE2018001060A PE2018001060A PE20181072A1 PE 20181072 A1 PE20181072 A1 PE 20181072A1 PE 2018001060 A PE2018001060 A PE 2018001060A PE 2018001060 A PE2018001060 A PE 2018001060A PE 20181072 A1 PE20181072 A1 PE 20181072A1
Authority
PE
Peru
Prior art keywords
solid preparation
diphenylpyrazin
butyloxy
isopropylamine
acetamide
Prior art date
Application number
PE2018001060A
Other languages
English (en)
Inventor
Shouji Furuta
Hironori Mukai
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59014064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20181072(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of PE20181072A1 publication Critical patent/PE20181072A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA PREPARACION SOLIDA QUE COMPRENDE: i) 2-{4-[N-(5,6-DIFENILPIRAZIN-2-IL)-N-ISOPROPILAMINO]BUTILOXI}-N-(METILSULFONIL)ACETAMIDA EN UNA CANTIDAD DE 0.1 A 2% EN PESO DE LA PREPARACION SOLIDA; ii) D-MANITOL EN UNA CANTIDAD DE 10 A 99% EN PESO DE LA PREPARACION SOLIDA; iii) UN DILUYENTE TAL COMO ALMIDON DE MAIZ EN UNA CANTIDAD DE 15 A 40% EN PESO DE LA PREPARACION SOLIDA; Y iv) UN AGLUTINANTE TAL COMO HIDROXIPROPIL CELULOSA EN UNA CANTIDAD DE 1 A 5% EN PESO DE LA PREPARACION SOLIDA. DICHA PREPARACION SOLIDA ES UNA TABLETA O UN GRANULO UTIL PARA EL TRATAMIENTO DE GANGRENA DIABETICA, TROMBOSIS, NEFROPATIA DIABETICA, INSUFICIENCIA RENAL CRONICA
PE2018001060A 2015-12-02 2016-12-01 Composicion farmaceutica que contiene 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}-n-(metilsulfonil)acetamida PE20181072A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015236034 2015-12-02

Publications (1)

Publication Number Publication Date
PE20181072A1 true PE20181072A1 (es) 2018-07-04

Family

ID=59014064

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001060A PE20181072A1 (es) 2015-12-02 2016-12-01 Composicion farmaceutica que contiene 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}-n-(metilsulfonil)acetamida

Country Status (22)

Country Link
US (2) US10821108B2 (es)
EP (3) EP3384911A4 (es)
JP (1) JP6825574B2 (es)
KR (1) KR102759845B1 (es)
CN (1) CN108289890B (es)
AU (1) AU2016366073B2 (es)
BR (1) BR112018009534B1 (es)
CA (1) CA3005169A1 (es)
CL (1) CL2018001464A1 (es)
CO (1) CO2018006834A2 (es)
EC (1) ECSP18049108A (es)
IL (2) IL310203A (es)
MX (1) MX385595B (es)
PE (1) PE20181072A1 (es)
PH (1) PH12018501161B1 (es)
RU (1) RU2735547C2 (es)
SA (1) SA518391686B1 (es)
SG (1) SG11201804320QA (es)
TW (1) TWI750143B (es)
UA (1) UA124002C2 (es)
WO (1) WO2017098998A1 (es)
ZA (1) ZA201804387B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190204A1 (ar) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
EP3711763A4 (en) 2017-11-16 2021-08-18 Nippon Shinyaku Co., Ltd. CONTROLLED RELEASE FORMULATION
AU2019225516A1 (en) 2018-02-21 2020-10-08 Nippon Shinyaku Co., Ltd. Granular composition, production method for granular composition, and dissolution property improvement method for granular composition
US20210069187A1 (en) * 2019-05-11 2021-03-11 RK Pharma Solutions LLC Stable pharmaceutical composition of Selexipag
MX2022004882A (es) * 2019-10-23 2022-08-04 Actelion Pharmaceuticals Ltd Composicion farmaceutica que comprende selexipag.
CN114051644B (zh) 2019-11-25 2024-03-15 埃赛克斯古河电磁线日本有限公司 绝缘电线、线圈和电气/电子设备
TW202203924A (zh) * 2020-04-10 2022-02-01 日商日本新藥股份有限公司 固形製劑及其製造方法
CN112220770B (zh) * 2020-12-17 2021-04-09 上海翰森生物医药科技有限公司 司来帕格的药物组合物及其制备方法
WO2022240378A1 (en) * 2021-05-11 2022-11-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi A stable pharmaceutical composition comprising selexipag

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3145431B2 (ja) 1991-08-20 2001-03-12 日本酸素株式会社 安定同位体標識蛋白質の製造法および試薬キット
JP3126683B2 (ja) * 1996-04-16 2001-01-22 武田薬品工業株式会社 Ｄ−マンニトールおよびその製造法
US20010001106A1 (en) 1996-04-16 2001-05-10 Tomohiro Yoshinari D-mannitol and its preparation
CA2408562A1 (en) 2000-05-19 2001-11-29 Thomas A. Boyd Dehydroascorbic acid formulations and uses thereof
PT1178047E (pt) 2000-08-03 2004-05-31 Pfizer Prod Inc Derivados diazabiciclooctano e seus usos terapeuticos
TWI316055B (es) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
US7112393B2 (en) 2003-07-29 2006-09-26 Canon Kabushiki Kaisha Non-magnetic toner
FR2918566B1 (fr) * 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
MX2010008745A (es) 2008-02-28 2010-08-30 Nippon Shinyaku Co Ltd Inhibidor de fibrosis.
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
LT2289518T (lt) * 2008-06-23 2017-01-10 Nippon Shinyaku Co., Ltd. Terapinis agentas nuo uždegiminės žarnų ligos
CN105168218A (zh) 2008-06-23 2015-12-23 日本新药株式会社 椎管狭窄症治疗剂
CN104326991A (zh) * 2009-06-26 2015-02-04 日本新药株式会社 晶体
US20150272874A1 (en) 2012-10-29 2015-10-01 Cardio Incorporated Pulmonary disease-specific therapeutic agent
CN103690496B (zh) 2013-12-27 2015-04-01 哈药集团生物工程有限公司 一种含有奥扎格雷钠的冻干药物组合物

Also Published As

Publication number Publication date
AU2016366073B2 (en) 2021-08-26
ECSP18049108A (es) 2018-10-31
JP6825574B2 (ja) 2021-02-03
NZ742784A (en) 2024-08-30
CO2018006834A2 (es) 2018-07-10
IL259461A (en) 2018-07-31
KR102759845B1 (ko) 2025-01-23
EP4331607A3 (en) 2024-05-29
EP4331607A2 (en) 2024-03-06
BR112018009534A2 (pt) 2018-11-06
US10821108B2 (en) 2020-11-03
IL310203A (en) 2024-03-01
US20180325895A1 (en) 2018-11-15
AU2016366073A1 (en) 2018-06-14
BR112018009534B1 (pt) 2023-11-07
SG11201804320QA (en) 2018-06-28
JPWO2017098998A1 (ja) 2018-09-20
KR20180081141A (ko) 2018-07-13
CA3005169A1 (en) 2017-06-15
CL2018001464A1 (es) 2018-10-19
CN108289890A (zh) 2018-07-17
MX385595B (es) 2025-03-18
EP4501404A3 (en) 2025-05-07
MX2018006343A (es) 2018-08-01
WO2017098998A1 (ja) 2017-06-15
SA518391686B1 (ar) 2024-03-03
PH12018501161B1 (en) 2024-07-03
RU2018123304A3 (es) 2020-04-02
RU2018123304A (ru) 2020-01-09
EP3384911A4 (en) 2019-05-15
EP4501404A2 (en) 2025-02-05
ZA201804387B (en) 2020-12-23
EP4331607B1 (en) 2025-04-30
PH12018501161A1 (en) 2019-01-21
TW201720444A (zh) 2017-06-16
US10828298B2 (en) 2020-11-10
US20180333413A1 (en) 2018-11-22
TWI750143B (zh) 2021-12-21
RU2735547C2 (ru) 2020-11-03
EP3384911A1 (en) 2018-10-10
UA124002C2 (uk) 2021-07-07
CN108289890B (zh) 2021-04-27

Similar Documents

Publication Publication Date Title
PE20181072A1 (es) Composicion farmaceutica que contiene 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}-n-(metilsulfonil)acetamida
PE20141822A1 (es) Inhibidor de la quinasa reguladora de la senal de apoptosis
NZ721298A (en) Pharmaceutical compositions comprising azd9291
EA201791261A1 (ru) 1,3-тиазол-2-ил замещенные бензамиды
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2011002989A1 (es) Compuestos heterociclicos inhibidores de la endopeptidasa neutra (nep); composicion farmaceutica; combinacion farmaceutica; uso del compuesto patra tratar un trastorno o enfermedad tal como hipertencion, insuficiencia cardiaca, insuficiencia renal, epilepsia, sindrome metabolico, entre otros.
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
EA201692388A1 (ru) Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
EA201791579A1 (ru) Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2 адренергических рецепторов
RU2014143536A (ru) Фармацевтическая композиция, содержащая омелсартана медоксомил и розувастатин или его соль
PE20100050A1 (es) Forma de dosificacion farmaceutica para la liberacion inmediata de un derivado de indolinona
RU2014138035A (ru) Твердая фармацевтическая композиция, содержащая 1-(3-(2-(1-бензотиофен-5-ил)этокси)пропил)азетидин-3-ол или его соль
BR112015029038A2 (pt) comprimido engolível, e, processo para preparação de um comprimido engolível
MX2017004614A (es) Preparacion compuesta, que contiene derivado novedoso de acido 3-(4-(benciloxi)fenil)hex-4-inoico y otro ingrediente activo, para prevenir o tratar enfermedades metabolicas.
CL2013001054A1 (es) Compuestos derivados de cianopirazoles, moduladores de la actividad del receptor gpr119 acoplado a la proteina g; composicion farmaceutica; y metodo para tratar una enfermedad, afeccion, o trastorno metabolico seleccionado de hiperlipidemia, diabetes tipo i, diabetes mellitus tipo ii, diabetes tipo i idiopatica, entre otras.
BR112016028037A2 (pt) Novos compostos
MX2019001781A (es) Compuestos de tiofeno condensado utiles como inhibidores de napi-iib.
PH12015501941A1 (en) Benzo-fused heterocyclic derivatives useful as agonists of gpr120
BR112014030160A2 (pt) composição formadora de película, uso de uma composição formadora de película, película e cápsula dura
AR096725A1 (es) Formulación de comprimidos masticables que comprende tadalafil o una de sus sales aceptables desde el punto de vista farmacéutico
MX378947B (es) Composición farmacéutica estable para administración oral.
BR112022008389A2 (pt) Uso de amidos de succinato de octenila sódico como um aglutinante na granulação a úmido contínua
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载